Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity

Boris Engels, Victor H. Engelhard, John Sidney, Alessandro Sette, David C. Binder, Rebecca B. Liu, David M. Kranz, Stephen C. Meredith, Donald A. Rowley, Hans Schreiber

Research output: Contribution to journalArticlepeer-review

Abstract

Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy.

Original languageEnglish (US)
Pages (from-to)516-526
Number of pages11
JournalCancer Cell
Volume23
Issue number4
DOIs
StatePublished - Apr 15 2013

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity'. Together they form a unique fingerprint.

Cite this